Auristatin antibody drug conjugate physical instability and the role of drug payload.
暂无分享,去创建一个
Kelly A. Schwarz | Thomas W Patapoff | T. Patapoff | William J Galush | Yilma T Adem | Osigwe Esue | Eileen Duenas | E. Duenas | Kelly A Schwarz | Osigwe Esue | W. Galush
[1] Peter D. Senter,et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy , 2003 .
[2] Aditya A Wakankar,et al. Analytical methods for physicochemical characterization of antibody drug conjugates , 2011, mAbs.
[3] Heather Flores,et al. Investigation into temperature-induced aggregation of an antibody drug conjugate. , 2013, Bioconjugate chemistry.
[4] Fred Jacobson,et al. Protein aggregation and bioprocessing , 2006, The AAPS Journal.
[5] Igor V. Tetko,et al. Virtual Computational Chemistry Laboratory – Design and Description , 2005, J. Comput. Aided Mol. Des..
[6] I. Hollander,et al. Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates. , 2008, Bioconjugate chemistry.
[7] Bernhardt L Trout,et al. Prediction of aggregation prone regions of therapeutic proteins. , 2010, The journal of physical chemistry. B.
[8] P. Trail,et al. Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains. , 2002, Journal of medicinal chemistry.
[9] Y. Oki,et al. Brentuximab vedotin in systemic T-cell lymphoma , 2012, Expert opinion on biological therapy.
[10] Randall J Mrsny,et al. Formulation and delivery issues for monoclonal antibody therapeutics. , 2006, Advanced drug delivery reviews.
[11] Gopi Shankar,et al. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs , 2007, Nature Biotechnology.
[12] P. Plotz,et al. The specificity of uptake of model immune complexes and other protein aggregates by the murine reticuloendothelial system. , 1980, Journal of immunology.
[13] Aditya A Wakankar,et al. Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes. , 2010, Bioconjugate chemistry.
[14] Paul Polakis,et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index , 2008, Nature Biotechnology.
[15] T. Ueda,et al. Effect of buffer species on the unfolding and the aggregation of humanized IgG. , 2007, Journal of biochemistry.
[16] P. Trail,et al. Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates. , 1999, Bioconjugate chemistry.
[17] P. Burke,et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. , 2013, Bioconjugate chemistry.
[18] Brian M. Murphy,et al. Stability of Protein Pharmaceuticals: An Update , 2010, Pharmaceutical Research.
[19] Uma Yasothan,et al. Brentuximab vedotin , 2022, Nature Reviews Drug Discovery.
[20] A. Vermeer,et al. The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein. , 2000, Biophysical journal.
[21] Damon L. Meyer,et al. Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.
[22] Xinxia Peng,et al. Effects of arginine on heat‐induced aggregation of concentrated protein solutions , 2011, Biotechnology progress.
[23] Michael M C Sun,et al. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. , 2005, Bioconjugate chemistry.
[24] Anna M Wu,et al. Arming antibodies: prospects and challenges for immunoconjugates , 2005, Nature Biotechnology.
[25] A. Bertolotti,et al. Exposure of Hydrophobic Surfaces Initiates Aggregation of Diverse ALS-Causing Superoxide Dismutase-1 Mutants , 2010, Journal of molecular biology.
[26] R. Ionescu,et al. Fragmentation of monoclonal antibodies , 2011, mAbs.
[27] W. J. Galush,et al. Profiling antibody drug conjugate positional isomers: a system-of-equations approach. , 2012, Analytical chemistry.
[28] A. Wahl,et al. Secondary mAb--vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway. , 2004, Bioconjugate chemistry.
[29] K. Imamura,et al. On the adsorption of proteins on solid surfaces, a common but very complicated phenomenon. , 2001, Journal of bioscience and bioengineering.
[30] Linda O Narhi,et al. High throughput thermostability screening of monoclonal antibody formulations. , 2010, Journal of pharmaceutical sciences.
[31] Colleen E. Price,et al. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. , 2008, Journal of pharmaceutical sciences.
[32] Hanns-Christian Mahler,et al. Protein aggregation: pathways, induction factors and analysis. , 2009, Journal of pharmaceutical sciences.
[33] Wei Wang,et al. Protein aggregation--pathways and influencing factors. , 2010, International journal of pharmaceutics.
[34] Bernhardt L. Trout,et al. Design of therapeutic proteins with enhanced stability , 2009, Proceedings of the National Academy of Sciences.
[35] Igor V Tetko,et al. Computing chemistry on the web. , 2005, Drug discovery today.